20 results about "Glycopeptide" patented technology

A FAP glycopeptide as represented by Formula (I), and a radionuclide marker thereof and the use thereof. The FAP glycopeptide is obtained by modifying a linker portion that forms a cyclic peptide on the basis of a polypeptide FAP-2286 structure, and further introducing mono- or di-saccharide molecules. After being marked with radionuclides, the glycopeptide shows superior tumor uptake and lower liver uptake compared to FAP-2286, resulting in better imaging outcomes, facilitating the development of candidate radionuclide pharmaceuticals with further research value, and contributing to the ultimate goal of developing FAP-targeted cyclic peptide radiopharmaceuticals with independent intellectual property rights. Drawing_references_to_be_translated

The present application relates to the technical field of microbial fermentation, in particular to a polyporus arctorus and a culture method and application thereof. A polyporus arctorus YH-DB-1 is screened in the present application, and a large amount of glycopeptide can be extracted from the mycelium of the strain by culturing the strain, the peptide content in the glycopeptide can reach more than 45%, and the present application solves the problem of low peptide yield in the existing polyporus arctorus glycopeptide.

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The application discloses a kind of bifunctional magnetic nano material and its preparation method and application.The nano material described in the application is Fe3O4@ZrO2@TiO2@mSiO2-L-Cys, with spherical structure;The material includes successively from inside to outside: the inner core is the magnetic nanoparticle of ferriferrous oxide;Intermediate layer is zirconium dioxide and titanium dioxide composite metal oxide layer;Sub-outer layer is mesoporous silica layer;The outermost layer is the L-cysteine molecular layer grafted by zirconium-sulfur chemical bond;The preparation method described in the application adopts solvothermal method to synthesize magnetic core, functional layer is coated by hydrothermal reaction, co-condensation method constructs mesoporous shell, and hydrophilic group is introduced by chemical grafting.The bifunctional magnetic mesoporous nano material prepared in the application is applied to the effective enrichment of glycopeptide and phosphopeptide in standard protease solution mixture, and the detection sensitivity of phosphopeptide and glycopeptide reaches 1 fmol / μL, which has wide prospect in glycopeptide and phosphopeptide proteomics analysis research.

The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.

The application discloses a kind of magnetic material for synchronously enriching glycopeptide and phosphopeptide and its preparation method and application.The nanomaterial Fe3O4@nSiO2@TiO2@mSiO2-L-Cys described in the application;The material includes successively from inside to outside: the magnetic core of ferriferrous oxide;Non mesoporous silica intermediate layer coated on the surface of the core;Titanium dioxide functional layer coated on the surface of the intermediate layer;And the outermost layer is the ordered radial dendritic mesoporous silica shell layer modified by L-cysteine;The preparation method described in the application adopts solvothermal method to synthesize magnetic core, functional layer is coated by hydrothermal reaction, co-condensation method is used to build mesoporous shell layer, and hydrophilic group is introduced by chemical grafting.The prepared magnetic material of the application is applied to the effective enrichment of glycopeptide and phosphopeptide in standard protease hydrolysis mixed liquor, and the detection sensitivity of phosphopeptide and glycopeptide reaches 0.1fmol / µL and 1fmol / µL respectively, which has wide prospect in glycopeptide and phosphopeptide proteomics analysis research.

The application belongs to the technical field of biological medicine, and discloses ovomucin glycopeptide and application. The application of the ovomucin glycopeptide in the preparation of a drug for preventing or treating alcohol-induced acute gastric mucosal injury is disclosed, and when used for protection, the percentage of the gastric mucosal injury area can be reduced to below 1.0%. The application creatively discovers and proves that the glycopeptide derived from ovomucin has a significant protective effect on alcohol-induced acute gastric mucosal injury. The discovery of the application explicitly expands the application field of the natural active ingredient ovomucin to the protection of acute gastric mucosal injury for the first time, solves the technical problem that there is a lack of efficient and natural gastric mucosal protective ingredients in the prior art, and provides a new material basis and a clear direction for developing a new gastric mucosal protective agent.

This invention relates to a biomimetic extracellular matrix hydrogel, its preparation method, and its application. The preparation method of this invention includes the following steps: (1) dissolving a natural high-molecular-weight polysaccharide in solvent A, then adding a halogenated oxyacid salt, and reacting in the dark; after the reaction is completed, adding ethylene glycol to terminate the reaction, dialyzing, and then freeze-drying to obtain GM-CHO powder; (2) dissolving the GM-CHO powder in solvent B, adding an amino acid polymer, and stirring at a constant temperature; then dialyzing and freeze-drying sequentially to obtain GMI glycopeptide; (3) dissolving the GMI glycopeptide and aminated glucomannan in solvent C, vortexing, and finally allowing it to stand at room temperature to form a biomimetic extracellular matrix hydrogel. The biomimetic extracellular matrix hydrogel of this invention can simultaneously achieve "correcting metabolic disorders, clearing pathogens, and simulating extracellular matrix", improving the retention time at the wound site and facilitating long-term therapeutic effects.

This invention discloses a method for preparing a ternary dynamic glycopeptide hydrogel bio-ink, comprising the following steps: dissolving methacrylamide gelatin, aldehyde-modified hyaluronic acid, hydrazide-modified gelatin, and a photoinitiator together in a solvent and mixing them evenly to obtain the bio-ink. This bio-ink constructs a dynamic covalent cross-linking network through reversible acylhydrazone bonds formed between aldehyde-modified hyaluronic acid and hydrazide-modified gelatin, providing a remodelable three-dimensional microenvironment for cells. Simultaneously, the photocrosslinking properties of methacrylic anhydride-modified gelatin are introduced to rapidly solidify and maintain overall shape stability during the printing stage, providing a remodelable cellular microenvironment during subsequent in vitro culture. This establishes an organoid culture platform with both good printability and excellent cell compatibility, providing a reliable material basis for subsequent drug screening and functional studies.

The present application relates to the field of nanotechnology, in particular to a raffinose-SS31 peptide multi-targeted functional chitooligosaccharide / astaxanthin nanoparticle and a preparation method and application thereof.The nanoparticle of the present application takes precise regulation at the nanometer scale, innovative application of new components and targeted synergistic delivery as the core design idea, constructs a multifunctional nanofunctional network, provides support for the nanoscale precise delivery of active ingredients such as astaxanthin, and at the same time, establishes a chitooligosaccharide nanoparticle preparation technology with high active substance loading rate and stability for the problems of low stability and poor efficacy of chitooligosaccharide encapsulated active substances;targeting ligands are introduced by structure modification to enhance the specific recognition and binding capacity of nanoparticles to specific cells and tissues, and a targeted delivery technology for site-specific release and precise delivery of active substances is established.

The application discloses a preparation method and application of a novel composite material of magnetic core-porous hydrophilic MOFs for serum glycopeptide analysis. First, based on the in-situ MOF growth strategy, the composite material with a magnetic inner core and a multistage-pore MOFs shell is synthesized. Then, the composite material is used for glycopeptide separation and enrichment of a target sample, and then MALDI-TOF MS analysis and LC-MS / MS analysis are carried out. The combination of the composite material and the robust enrichment process can realize ultra-low detection limit (1 amol / μL) and ultra-high repeatability (CV<15%) of glycopeptides, and the finally detected serum glycopeptides can be further used for screening of disease-related differential expression markers.

The application discloses an O-GlcNAc modified peptide segment enrichment method and analysis method based on chemical enzymatic labeling and reversible oxime bond formation. The method comprises the following steps: removing N-glycan chains of a peptide segment mixture by using a glycosidase to obtain an N-glycan chain removed peptide segment mixture; mixing the N-glycan chain removed peptide segment mixture, UDP-GalNLeV and Gal-T1-Y289L mutant to perform an enzymatic labeling reaction to obtain a mixture containing ketone labeled O-GlcNAc peptide segments; covalently capturing the ketone labeled O-GlcNAc peptide segment mixture by using a solid phase carrier of allyl hydroxylamine, washing to obtain a solid phase carrier loaded with peptide segments; reacting the solid phase carrier loaded with peptide segments with a reagent containing a hydroxylamine group, collecting a release liquid, desalting to obtain O-GlcNAc peptide segments labeled by a methoxy oxime bond. The application realizes one-step labeling and reversible enrichment of O-GlcNAc modified peptide segments, and improves the coverage of glycopeptide identification.

The present invention belongs to the technical field of biology, and particularly relates to a compound for treating myocardial infarction. A chondroitin sulfate oligosaccharide in the present invention is extracted from natural chondroitin sulfate. After the chondroitin sulfate oligosaccharide is treated by a chemically enzymatic process into an oligosaccharide chain, experiments prove that the chondroitin sulfate oligosaccharide contributes to the survival of cardiomyocytes. Compared with other products with similar functions, a glycopeptide polymer hydrogel formed after the introduction of a polymer backbone overcomes the problem of batch-to-batch differences of natural products and has a definite structure. Moreover, the hydrogel has excellent inherent biological activity, and does not need to load active ingredients such as other drugs. The hydrogel exhibits an obvious effect on supporting the ventricular wall in an infarcted area and promoting the survival of cardiomyocytes, and can effectively limit the area of myocardial infarction, increase the ventricular wall thickness of the infarcted area, and alleviate cardiac damage caused by myocardial infarction, and therefore has a good application prospect.

The application provides biomarkers for diagnosing systemic lupus erythematosus and application thereof, and belongs to the field of biological medicine. The biomarkers are at least one of the following five proteins N-glycopeptides, specifically: IgG1_N299-HexNAc(3)Hex(4); F2_N121-HexNAc(2)Hex(12); C3_N85-HexNAc(2)Hex(1); VTN_N169-HexNAc(2)Hex(4); APOB_N1523-HexNAc(3)Hex(4)NeuAc(1). The application proposes the five protein N-glycopeptides as biomarkers for diagnosing SLE, and has the advantages of high accuracy, high sensitivity and high specificity, and provides a new target for the diagnosis and intervention improvement of SLE patients.

This invention discloses a method and application for the chemical enzymatic synthesis of O-glycopeptides, belonging to the field of pharmaceutical technology. The method includes the following steps: assembling a polypeptide intermediate using a solid-phase polypeptide synthesis method, wherein the amino acids at non-glycosylated active sites in the polypeptide intermediate are protected by sterically hindered protecting groups, while the hydroxyl groups on the amino acids at predetermined glycosylation sites are unprotected; glycosylation of the polypeptide intermediate with a glyconucleotide donor in the presence of a glycosyltransferase to obtain a glycopeptide intermediate; and reacting the glycopeptide intermediate with a deprotecting agent to remove the sterically hindered protecting groups, thus obtaining the target glycopeptide. This invention uses amino acids modified with protecting groups as raw materials, selectively protects the active hydroxyl sites in the amino acids, prepares polypeptide intermediates through solid-phase polypeptide synthesis, efficiently and accurately synthesizes the target glycopeptide intermediate with the help of glycosyltransferase synergistic catalysis, and finally obtains the target glycopeptide by removing the protecting groups through a catalyst.

The present invention relates to monoclonal antibodies reactive with glycopeptides and uses thereof. The present invention provides monoclonal antibodies that have as epitopes both the fucose moiety and the amino acids of the peptide moiety of a glycopeptide. The monoclonal antibodies are reactive with (a) glycopeptides of the formula: 【Chemical 1】 but not with (b) glycopeptides of the formula: 【Chemical 2】

This invention relates to the field of glycopeptide composition technology, specifically to a small molecule glycopeptide composition derived from bird's nest, its preparation method, and its applications. A method for preparing a small molecule glycopeptide composition derived from bird's nest includes: cleaning, soaking, and extracting the bird's nest raw material; enzymatic hydrolysis; enrichment and impurity removal; and ultrafiltration purification. In the purification stage, this invention uses a modified covalent organic framework as an adsorbent. Boric acid groups can target and capture glycopeptides, eliminating impurities without cis-diol structures, solving the problems of poor selectivity and high loss rate in traditional methods, and reducing the load on subsequent steps. Chitosan modification prevents framework aggregation, and its polar groups synergistically enhance adsorption capacity and specificity with the framework groups, improving product purity. Proline-modified chitosan can break intermolecular hydrogen bonds, ensuring uniform coating. Through multiple effects, it strengthens adsorption specificity and capacity, effectively enriching glycopeptides and reducing impurities, laying the foundation for high product yield, high purity, and effective biological function.

This utility model relates to the technical field of goji berry processing equipment, specifically disclosing a pulverizing tank and preparation system for goji berry glycopeptide preparation. The pulverizing tank includes a tank body and a goji berry pulverizing mechanism disposed within the tank body. The pulverizing mechanism includes a motor, a pulverizing roller, and a steel cylinder. The motor is disposed within the tank body, and the pulverizing roller is rotatably disposed inside the steel cylinder and connected to the motor's output end. The steel cylinder is disposed inside the tank body, with its lower end connected to a slag discharge pipe disposed at the lower end of the tank body, and its upper end being an open end connected to both the tank body's feed inlet and water inlet. The pulverizing tank enables slag-liquid separation, effectively reducing the workload of subsequent centrifuge tanks and providing reliable technical support for the goji berry glycopeptide preparation system. It solves the problem that existing crushing drums cannot effectively separate goji berry residue after pulping and pulverizing, resulting in excessively high residue content in the subsequent slurry and reduced separation efficiency.